Key result
This review highlights preclinical and clinical evidence suggesting that low-molecular-weight heparins may improve survival in cancer patients through direct effects on tumor biology.
Why the study?
Do low-molecular-weight heparins improve survival in patients with malignancy through antitumoral effects?
Do low-molecular-weight heparins improve survival in patients with malignancy through antitumoral effects?
This review highlights the potential for low-molecular-weight heparins to provide survival benefits in cancer patients via direct antitumoral mechanisms independent of their antithrombotic effects.
Answers are grounded in this paper and cite their sources.
LMWHs should not yet change cancer management for survival; leaves open antitumoral benefits pending randomized confirmation.
A close relationship between cancer and thrombosis does exist, documented by the fact that an overall 7-fold increased risk of venous thromboembolism (VTE) has been reported in patients with malignancy compared to non-malignancy. The potential impact of antithrombotic agents in cancer-associated VTE has long been recognized, and, in particular, several clinical trials in the last 20 years have reported the safety and efficacy of low-molecular-weight heparins (LMWHs) for treatment and prophylaxis of VTE in patients with various types of cancer. More recently, a number of preclinical and clinical studies have suggested that LMWHs may improve survival in cancer patients with mechanisms that are different from its antithrombotic effect but are linked to the ability of influencing directly the tumor biology. This paper reviews the evidence around the potential survival benefits of LMWHs by analyzing the suggested mechanisms and the available clinical data.
No takes yet. Share an insight, caveat, or question.
Franchini et al. (2015) conducted a review in Cancer and venous thromboembolism. Low-molecular-weight heparins (LMWHs) was evaluated on Survival benefits and antitumoral effect. This review highlights preclinical and clinical evidence suggesting that low-molecular-weight heparins may improve survival in cancer patients through direct effects on tumor biology.
Synapse has enriched 10 related papers. Consider them for comparative context: